Research Article: GLP-RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT Pathway
Abstract:
Obesity (defined as BMI ? kg/m) is a chronic disease characterized by abnormal body fat or over-accumulation, which affects more than billion people worldwide. Due to a sedentary lifestyle, adipose tissue disorders, comorbidities (acute and chronic diseases) and metabolic changes during aging, loss of skeletal muscle mass and function (sarcopenia) is common in obese patients. The decrease in muscle mass/function coexists with an increase in fat mass, is referred to as sarcopenic obesity (SO). Compared to obesity alone, SO is associated with an increased risk of adverse health consequences, such as disability, cardiovascular metabolic diseases, other comorbidities and mortality. The deposition of ectopic fat caused by obesity can lead to biological dysfunction of skeletal muscles, including inflammation, insulin resistance (IR) and oxidative stress. These changes further exacerbate the loss of skeletal muscles and physical dysfunction. Therefore, a deep understanding of the potential mechanisms of SO is crucial for its accurate diagnosis, effective prevention and treatment. Currently, the main treatment for SO is lifestyle intervention, including calorie restriction and physical activity. However, there are still some limitations in the treatment of SO. Therefore, determining the therapeutic targets of SO has attracted widespread attention.
Introduction:
Obesity (defined as BMI ? kg/m ) is a chronic disease characterized by abnormal body fat or over-accumulation, which affects more than billion people worldwide. Due to a sedentary lifestyle, adipose tissue disorders, comorbidities (acute and chronic diseases) and metabolic changes during aging, loss of skeletal muscle mass and function (sarcopenia) is common in obese patients. The decrease in muscle mass/function coexists with an increase in fat mass, is referred to as sarcopenic obesity (SO). Compared to obesity…
Read more